Neptune to Hold Conference Call

Neptune to Hold Conference Call

LAVAL, Quebec, Nov. 26, 2012 (GLOBE NEWSWIRE) -- Neptune Technologies &
Bioressources Inc. ("Neptune") (Nasdaq:NEPT) (TSX:NTB) will be holding a
conference call on Tuesday November 27, 2012 at 9:00AM ET. The call will focus
solely on the presentation of Neptune action plan to resume operations.

The conference call hosts will be:

  *Henri Harland, President & CEO
  *André Godin, CFO
  *Harlan Waksal, Board Member

To access the conference call by phone within Canada & the U.S., the toll‐free
number is 1‐877-380-5664. Outside Canada and the U.S., dial 1‐631-813-4882

Conference call details:

Conference Topic: Neptune Technologies & Bioressources - Announcement

Conference ID: 75271239

Management will not accept questions at the end of the presentation.

An archived recording of the webcast will be available on Neptune's website
( shortly after the webcast.

About Neptune Technologies & Bioressources Inc.

Neptune is a biotechnology company engaged primarily in the development and
commercialization of marine-derived omega-3 polyunsaturated fatty acids, or
PUFAs. Neptune has a patented process of extracting oils from Antarctic krill,
which omega-3 PUFAs are then principally sold as bulk oil to Neptune's
distributors who commercialize them under their private label primarily in the
U.S., European and Australian neutraceutical markets. Neptune's lead products,
Neptune Krill Oil (NKO®) and ECOKRILL Oil (EKO™), generally come in capsule
form and serve as a dietary supplement to consumers.

Through its subsidiaries Acasti (TSXV:APO) and NeuroBio, in which Neptune
respectively holds 57% and 99% of the voting rights, Neptune is also pursuing
opportunities in the medical food and prescription drug markets. Acasti and
NeuroBio respectively focus on the research and development of safe and
therapeutically effective compounds for highly prevalent atherosclerotic
conditions, such as cardiometabolic disorders and cardiovascular diseases, and
for neurodegenerative and inflammation related conditions. Acasti's lead
prescription drug candidate is CaPre®, a purified high omega-3 phospholipid
concentrate derived from Neptune krill oil being developed to address the
prevention and treatment of cardiometabolic disorders, including
hypertriglyceridemia, which is characterized by abnormally high levels of

CONTACT: Neptune Contact:
         Neptune Technologies & Bioressources Inc.
         Andre Godin, CFO
         Neptune Technologies & Bioressources Inc.
         Jean-Daniel Belanger
         Director, Securities and Corporate Affairs
         Neptune Technologies & Bioressources Inc.
         Frederic Harland, Director of Finance
Press spacebar to pause and continue. Press esc to stop.